Developer docs
API playgroundTry for free, no card

Search company profiles

Hypha Discovery

Full company profile

uuid000hnrd

Namestring
Hypha Discovery
Legal namestring
Hypha Discovery
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Hypha Discovery is a UK-based specialist Contract Research Organization (CRO) that provides metabolite synthesis, purification, and metabolite identification (MetID) services to the global pharmaceutical and agrochemical industries. Founded in 2004 and headquartered in Slough with 11-50 employees, the firm generates revenue through a mix of project-based professional services (MetID, metabolite synthesis, purification with Certificates of Analysis, contract fermentation, custom natural product synthesis) and catalog sales of proprietary screening kits (PolyCYPs®+, PolyUGTs) and recombinant enzymes (Human AOX1, Human FMOs). Named enterprise customers include Incyte, Alkermes, and Crestone, and the company states it has worked with many of the top global pharma and agrochemical companies.

Hypha's core technology platform is built around enzyme-based metabolite production. The PolyCYPs®+ kit combines 18 CYP isoforms with human aldehyde oxidase (AOX1) and FMO3, while the PolyUGTs kit covers 11 enzymes validated for O-, acyl-, and N-glucuronidation. These enzyme panels are complemented by chemical synthesis, microbial and mammalian biotransformation (S9 fractions and microsomes), late-stage functionalisation techniques (PolarExplorer, deoxyfluorination), and quantitative NMR spectroscopy for definitive structure elucidation. The integrated workflow enables production of difficult-to-synthesise metabolites at scale and supports regulatory-grade deliverables.

The commercial motion is direct B2B field sales into R&D departments of pharmaceutical and agrochemical enterprises, supported by content marketing (Metabolite Tales blog), quarterly newsletters, webinars, conference participation, publications, and case studies. Pricing is not publicly disclosed and is quote-based per project. The firm distributes globally from its UK base and sells screening kits directly via its website. Recent activity in 2026, including a quarterly newsletter cadence focused on LC-MS/MS MetID and PROTAC MetID, a Scientific Fellow hire, and active product launches, indicates ongoing reinvestment in both scientific depth and commercial reach.

Short descriptiontext

Hypha Discovery is a UK-based specialist CRO that produces drug and pesticide metabolites and derivatives for global pharmaceutical and agrochemical companies, combining proprietary enzyme screening kits with biotransformation and NMR-based structure elucidation services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAbingdon, United Kingdom
HQ citystring
Abingdon
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
metabolite synthesis services, contract research organization, metabolite identification CRO, drug biotransformation services, agrochemical metabolite synthesis
Industry3 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Laboratory Analytical Instruments3826
Product category
Drug Metabolism Contract Research Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model6 records
1MetID Services
TypeProfessional Services
Description

End-to-end metabolite identification services supporting clients across drug discovery and development, from pinpointing metabolic soft spots in early-stage compounds to detailed biotransformation studies using LC-MS/MS and NMR spectroscopy.

hyphadiscovery.com
2Metabolite Synthesis
TypeProfessional Services
Description

Custom synthesis of CYP and non-CYP phase 1 metabolites, glucuronides and other conjugates, and mixed pathway metabolites using chemical synthesis, recombinant enzymes, microbial and mammalian biotransformation.

hyphadiscovery.com
3Purification Services
TypeProfessional Services
Description

Purification from complex matrices with purity assessments by UV/ELSD/NMR and Certificates of Analysis.

hyphadiscovery.com
4Screening Kits (PolyCYPs, PolyUGTs)
TypeHardware Sales
Description

Sale of proprietary screening kit products for scientists to produce metabolites in their own laboratories. UDPGA co-factor included; fully scalable.

hyphadiscovery.com
5Custom Natural Product Synthesis
TypeProfessional Services
Description

Acquisition, storage and maintenance of strains; strain improvement and fermentation optimisation; purification and identification services.

hyphadiscovery.com
6Contract Fermentation
TypeProfessional Services
Description

Fermentation services for natural product and metabolite production.

hyphadiscovery.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1PolyCYPs®+
Description

Screening kits providing a quick and convenient way to access CYP-derived and other phase I metabolites. Kits comprise 18 PolyCYP isoforms together with human aldehyde oxidase (AOX1) and the main human hepatic flavin-containing monooxygenase (FMO3).

hyphadiscovery.com
+4 more records
Core offering1 text field

Hypha Discovery is a UK-based Contract Research Organization (CRO) that delivers custom metabolite synthesis, purification, and identification (MetID) services for pharmaceutical and agrochemical R&D clients. The company combines chemical synthesis, recombinant enzymes (including its proprietary PolyCYPs and PolyUGTs screening kits), and microbial/mammalian biotransformation to produce drug and pesticide metabolites, including difficult-to-synthesise CYP and non-CYP phase I metabolites, glucuronides, and conjugates, with structure elucidation by LC-MS/MS and quantitative NMR.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Delivered 60mg of phase I metabolite and over 100mg of phase II metabolite at high purity for Incyte Corporation
Product overview1 text field

Hypha Discovery operates as a specialist CRO (Contract Research Organization) offering a comprehensive suite of metabolite synthesis and identification services. The company's product portfolio includes PolyCYPs®+ Screening Kits for CYP-derived phase I metabolites, PolyUGTs Screening Kits for glucuronide production, Human Aldehyde Oxidase (AOX1), and Human FMOs. These products complement their service offerings which include MetID Services (LC-MS/MS and NMR-based metabolite identification), Metabolite Synthesis (CYP/non-CYP phase I, glucuronides, conjugates), Purification, Structure Elucidation and NMR, Late-Stage Functionalisation (PolarExplorer, Deoxyfluorination), Custom Natural Product Synthesis, Contract Fermentation, and Certificates of Analysis. The product kits enable scientists to produce metabolites in their own laboratories while the service offerings provide end-to-end expertise for pharmaceutical and agrochemical R&D.

Product and service12 records
1PolyCYPs®+ Screening Kits
CategoryEnzyme Screening Kit Product
Description

Screening kits providing a quick and convenient way for scientists to access CYP-derived and other phase I metabolites. Kits comprise 18 PolyCYP isoforms together with human aldehyde oxidase (AOX1) and the main human hepatic flavin-containing monooxygenase (FMO3), and are scalable for metabolite production in customer laboratories.

2PolyUGTs Screening Kits
CategoryEnzyme Screening Kit Product
Description

Screening kits used to screen for and scale up production of glucuronides of drugs, agrochemicals and other small molecules. The 11 enzymes in the kit have been tested for biocatalytic activity including O-glucuronidation of alkyl and phenolic hydroxyls, acyl-glucuronidation of carboxylic acids, and N-glucuronidation of aromatic nitrogen-containing systems. UDPGA co-factor is included.

3PolyCYPs Kits for Late-Stage Oxidation
CategoryEnzyme Screening Kit Product
Description

Specialized PolyCYPs kits configured for late-stage oxidation reactions, enabling production of hydroxylated and other oxidised derivatives of lead compounds for medicinal chemistry applications.

4Human Aldehyde Oxidase (AOX1)
CategoryRecombinant Enzyme Product
Description

Recombinant human aldehyde oxidase enzyme product for metabolite synthesis and biotransformation studies.

5Human FMOs
CategoryRecombinant Enzyme Product
Description

Human flavin-containing monooxygenases including FMO3 and other isoforms sold as recombinant enzyme products for metabolite production.

6MetID (Metabolite Identification) Services
CategoryCRO Service
Description

End-to-end metabolite identification services supporting drug discovery and development, from pinpointing metabolic soft spots in early-stage compounds through detailed biotransformation studies using LC-MS/MS and NMR spectroscopy. Delivered to pharmaceutical and agrochemical R&D clients.

7Metabolite Synthesis Services
CategoryCRO Service
Description

Custom synthesis of CYP and non-CYP phase I metabolites, glucuronides and other conjugates, and mixed pathway metabolites using chemical synthesis, recombinant enzymes, microbial biotransformation, and mammalian biotransformation. Scalable synthesis of difficult-to-produce metabolites is a core capability.

8Metabolite Purification Services
CategoryCRO Service
Description

Purification of metabolites from complex matrices with purity assessments by UV/ELSD/NMR and issuance of Certificates of Analysis.

9Late-Stage Functionalisation Services (PolarExplorer and Deoxyfluorination)
CategoryCRO Service
Description

Late-stage functionalisation services including PolarExplorer (facile generation of hydroxylated compounds on complex molecular cores) and Deoxyfluorination (selective fluorination of organic compounds) for medicinal chemistry SAR expansion.

10Structure Elucidation / NMR Spectroscopy Services
CategoryCRO Service
Description

Definitive structure elucidation, interpretation and documentation of spectra using state-of-the-art NMR instrumentation including quantitative NMR for metabolite identification and regulatory-grade documentation.

11Custom Natural Product Synthesis Services
CategoryCRO Service
Description

Acquisition, storage and maintenance of microbial strains; strain improvement and fermentation optimisation; purification and identification services for natural products.

12Contract Fermentation Services
CategoryCRO Service
Description

Contract fermentation services for natural product and metabolite production using Hypha's maintained microbial strains and fermentation capabilities.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialist DMPK/metabolism CRO offering in vitro ADME and metabolite identification services and related reagent products. Direct competitor to Hypha in drug-metabolite production and characterization for pharma clients.

TypeDirect peer
Description

Supplies biological specimens and offers metabolism/biotransformation research services to pharma. Comparable use cases in metabolite standards and drug-metabolism studies position it as a direct specialized peer.

3Absorption Systems (Eurofins Discovery)
TypeDirect peer
Description

Preclinical CRO focused on drug absorption, metabolism, and pharmacokinetics including MetID. Acquired by Eurofins, it directly overlaps Hypha's MetID and biotransformation service portfolio.

TypeBroad incumbent
Description

Broad discovery CRO offering ADME/PK, metabolite identification, medicinal chemistry and in vitro pharmacology. Larger incumbent that competes for the same pharma and agrochem sponsor budgets.

TypeBroad incumbent
Description

Large preclinical CRO offering DMPK, safety assessment, and discovery services. Competes with Hypha on metabolite identification and broader preclinical outsourcing packages.

TypeBroad incumbent
Description

Global CRO/CDMO with full-spectrum discovery, DMPK and manufacturing services. Overlaps Hypha's MetID, metabolite synthesis and agrochemical R&D support offerings.

TypeBroad incumbent
Description

Large contract discovery and development platform including in vitro ADME/DMPK and chemistry services. Represents a scaled incumbent in metabolite-related CRO work.

TypeBroad incumbent
Description

Diversified life-sciences services giant offering drug discovery, DMPK and analytical services via Patheon/PPD. Broad incumbent that competes for enterprise preclinical outsourcing contracts.

TypeDirect peer
Description

Preclinical CRO offering DMPK, metabolite identification and safety services. Operates as a mid-size services peer with comparable study types and customer base.

TypeRegional player
Description

India-based discovery and development CRO providing DMPK/ADME, custom synthesis and biotransformation services. Operates from a different geography than Hypha but competes for similar global outsourced DMPK programs.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hypha Discovery

Drug Metabolism Contract Research Serviceshyphadiscovery.co.uk

Hypha Discovery is a UK-based specialist CRO that produces drug and pesticide metabolites and derivatives for global pharmaceutical and agrochemical companies, combining proprietary enzyme screening kits with biotransformation and NMR-based structure elucidation services.

What Hypha Discovery does

Hypha Discovery is a UK-based specialist Contract Research Organization (CRO) that provides metabolite synthesis, purification, and metabolite identification (MetID) services to the global pharmaceutical and agrochemical industries. Founded in 2004 and headquartered in Slough with 11-50 employees, the firm generates revenue through a mix of project-based professional services (MetID, metabolite synthesis, purification with Certificates of Analysis, contract fermentation, custom natural product synthesis) and catalog sales of proprietary screening kits (PolyCYPs®+, PolyUGTs) and recombinant enzymes (Human AOX1, Human FMOs). Named enterprise customers include Incyte, Alkermes, and Crestone, and the company states it has worked with many of the top global pharma and agrochemical companies.

Hypha's core technology platform is built around enzyme-based metabolite production. The PolyCYPs®+ kit combines 18 CYP isoforms with human aldehyde oxidase (AOX1) and FMO3, while the PolyUGTs kit covers 11 enzymes validated for O-, acyl-, and N-glucuronidation. These enzyme panels are complemented by chemical synthesis, microbial and mammalian biotransformation (S9 fractions and microsomes), late-stage functionalisation techniques (PolarExplorer, deoxyfluorination), and quantitative NMR spectroscopy for definitive structure elucidation. The integrated workflow enables production of difficult-to-synthesise metabolites at scale and supports regulatory-grade deliverables.

The commercial motion is direct B2B field sales into R&D departments of pharmaceutical and agrochemical enterprises, supported by content marketing (Metabolite Tales blog), quarterly newsletters, webinars, conference participation, publications, and case studies. Pricing is not publicly disclosed and is quote-based per project. The firm distributes globally from its UK base and sells screening kits directly via its website. Recent activity in 2026, including a quarterly newsletter cadence focused on LC-MS/MS MetID and PROTAC MetID, a Scientific Fellow hire, and active product launches, indicates ongoing reinvestment in both scientific depth and commercial reach.

Hypha Discovery firmographics

Firmographics
Name
Hypha Discovery
Legal name
Hypha Discovery
Website
https://hyphadiscovery.co.uk
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Short description
Hypha Discovery is a UK-based specialist CRO that produces drug and pesticide metabolites and derivatives for global pharmaceutical and agrochemical companies, combining proprietary enzyme screening kits with biotransformation and NMR-based structure elucidation services.
Ownership category
akta.pro rank

Hypha Discovery industry classification

Industry
Product category
Drug Metabolism Contract Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Metabolite synthesis services
  • Contract research organization
  • Metabolite identification CRO
  • Drug biotransformation services
  • Agrochemical metabolite synthesis

Where Hypha Discovery is headquartered

Location

Headquarters

HQ city
Abingdon
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Hypha Discovery business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. MetID Services: End-to-end metabolite identification services supporting clients across drug discovery and development, from pinpointing metabolic soft spots in early-stage compounds to detailed biotransformation studies using LC-MS/MS and NMR spectroscopy.
  2. Metabolite Synthesis: Custom synthesis of CYP and non-CYP phase 1 metabolites, glucuronides and other conjugates, and mixed pathway metabolites using chemical synthesis, recombinant enzymes, microbial and mammalian biotransformation.
  3. Purification Services: Purification from complex matrices with purity assessments by UV/ELSD/NMR and Certificates of Analysis.
  4. Screening Kits (PolyCYPs, PolyUGTs): Sale of proprietary screening kit products for scientists to produce metabolites in their own laboratories. UDPGA co-factor included; fully scalable.
  5. Custom Natural Product Synthesis: Acquisition, storage and maintenance of strains; strain improvement and fermentation optimisation; purification and identification services.
  6. Contract Fermentation: Fermentation services for natural product and metabolite production.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels9 records

Hypha Discovery product offering

Product offering

Core offering

Hypha Discovery is a UK-based Contract Research Organization (CRO) that delivers custom metabolite synthesis, purification, and identification (MetID) services for pharmaceutical and agrochemical R&D clients. The company combines chemical synthesis, recombinant enzymes (including its proprietary PolyCYPs and PolyUGTs screening kits), and microbial/mammalian biotransformation to produce drug and pesticide metabolites, including difficult-to-synthesise CYP and non-CYP phase I metabolites, glucuronides, and conjugates, with structure elucidation by LC-MS/MS and quantitative NMR.

Product overview

Hypha Discovery operates as a specialist CRO (Contract Research Organization) offering a comprehensive suite of metabolite synthesis and identification services. The company's product portfolio includes PolyCYPs®+ Screening Kits for CYP-derived phase I metabolites, PolyUGTs Screening Kits for glucuronide production, Human Aldehyde Oxidase (AOX1), and Human FMOs. These products complement their service offerings which include MetID Services (LC-MS/MS and NMR-based metabolite identification), Metabolite Synthesis (CYP/non-CYP phase I, glucuronides, conjugates), Purification, Structure Elucidation and NMR, Late-Stage Functionalisation (PolarExplorer, Deoxyfluorination), Custom Natural Product Synthesis, Contract Fermentation, and Certificates of Analysis. The product kits enable scientists to produce metabolites in their own laboratories while the service offerings provide end-to-end expertise for pharmaceutical and agrochemical R&D.

Differentiator

Problem solved

Functional benefit

Brands

  • PolyCYPs®+: Screening kits providing a quick and convenient way to access CYP-derived and other phase I metabolites. Kits comprise 18 PolyCYP isoforms together with human aldehyde oxidase (AOX1) and the main human hepatic flavin-containing monooxygenase (FMO3).
  • PolyUGTs
  • PolarExplorer
  • Human Aldehyde Oxidase (AOX1)
  • Human FMOs

Products and services

  • PolyCYPs®+ Screening Kits Screening kits providing a quick and convenient way for scientists to access CYP-derived and other phase I metabolites. Kits comprise 18 PolyCYP isoforms together with human aldehyde oxidase (AOX1) and the main human hepatic flavin-containing monooxygenase (FMO3), and are scalable for metabolite production in customer laboratories.
  • PolyUGTs Screening Kits Screening kits used to screen for and scale up production of glucuronides of drugs, agrochemicals and other small molecules. The 11 enzymes in the kit have been tested for biocatalytic activity including O-glucuronidation of alkyl and phenolic hydroxyls, acyl-glucuronidation of carboxylic acids, and N-glucuronidation of aromatic nitrogen-containing systems. UDPGA co-factor is included.
  • PolyCYPs Kits for Late-Stage Oxidation Specialized PolyCYPs kits configured for late-stage oxidation reactions, enabling production of hydroxylated and other oxidised derivatives of lead compounds for medicinal chemistry applications.
  • Human Aldehyde Oxidase (AOX1) Recombinant human aldehyde oxidase enzyme product for metabolite synthesis and biotransformation studies.
  • Human FMOs Human flavin-containing monooxygenases including FMO3 and other isoforms sold as recombinant enzyme products for metabolite production.
  • MetID (Metabolite Identification) Services End-to-end metabolite identification services supporting drug discovery and development, from pinpointing metabolic soft spots in early-stage compounds through detailed biotransformation studies using LC-MS/MS and NMR spectroscopy. Delivered to pharmaceutical and agrochemical R&D clients.
  • Metabolite Synthesis Services Custom synthesis of CYP and non-CYP phase I metabolites, glucuronides and other conjugates, and mixed pathway metabolites using chemical synthesis, recombinant enzymes, microbial biotransformation, and mammalian biotransformation. Scalable synthesis of difficult-to-produce metabolites is a core capability.
  • Metabolite Purification Services Purification of metabolites from complex matrices with purity assessments by UV/ELSD/NMR and issuance of Certificates of Analysis.
  • Late-Stage Functionalisation Services (PolarExplorer and Deoxyfluorination) Late-stage functionalisation services including PolarExplorer (facile generation of hydroxylated compounds on complex molecular cores) and Deoxyfluorination (selective fluorination of organic compounds) for medicinal chemistry SAR expansion.
  • Structure Elucidation / NMR Spectroscopy Services Definitive structure elucidation, interpretation and documentation of spectra using state-of-the-art NMR instrumentation including quantitative NMR for metabolite identification and regulatory-grade documentation.
  • Custom Natural Product Synthesis Services Acquisition, storage and maintenance of microbial strains; strain improvement and fermentation optimisation; purification and identification services for natural products.
  • Contract Fermentation Services Contract fermentation services for natural product and metabolite production using Hypha's maintained microbial strains and fermentation capabilities.

Quantifiable outcome

  • Delivered 60mg of phase I metabolite and over 100mg of phase II metabolite at high purity for Incyte Corporation

Companies that use Hypha Discovery

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Hypha Discovery technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Hypha Discovery partnerships and signals

Strategic signal

Scale indicators1 record

Expansion highlights4 records

Hypha Discovery competitors and assessment

Company assessment

Direct peers

  • Sekisui Xenotech: Specialist DMPK/metabolism CRO offering in vitro ADME and metabolite identification services and related reagent products. Direct competitor to Hypha in drug-metabolite production and characterization for pharma clients.
  • BioIVT (BioreclamationIVT): Supplies biological specimens and offers metabolism/biotransformation research services to pharma. Comparable use cases in metabolite standards and drug-metabolism studies position it as a direct specialized peer.
  • Absorption Systems (Eurofins Discovery): Preclinical CRO focused on drug absorption, metabolism, and pharmacokinetics including MetID. Acquired by Eurofins, it directly overlaps Hypha's MetID and biotransformation service portfolio.
  • Inotiv: Preclinical CRO offering DMPK, metabolite identification and safety services. Operates as a mid-size services peer with comparable study types and customer base.

Broad incumbents

  • Eurofins Discovery: Broad discovery CRO offering ADME/PK, metabolite identification, medicinal chemistry and in vitro pharmacology. Larger incumbent that competes for the same pharma and agrochem sponsor budgets.
  • Charles River Laboratories: Large preclinical CRO offering DMPK, safety assessment, and discovery services. Competes with Hypha on metabolite identification and broader preclinical outsourcing packages.
  • Pharmaron: Global CRO/CDMO with full-spectrum discovery, DMPK and manufacturing services. Overlaps Hypha's MetID, metabolite synthesis and agrochemical R&D support offerings.
  • WuXi AppTec: Large contract discovery and development platform including in vitro ADME/DMPK and chemistry services. Represents a scaled incumbent in metabolite-related CRO work.
  • Thermo Fisher Scientific (Patheon / PPD): Diversified life-sciences services giant offering drug discovery, DMPK and analytical services via Patheon/PPD. Broad incumbent that competes for enterprise preclinical outsourcing contracts.

Regional players

  • Sai Life Sciences: India-based discovery and development CRO providing DMPK/ADME, custom synthesis and biotransformation services. Operates from a different geography than Hypha but competes for similar global outsourced DMPK programs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Hypha Discovery social profiles

Digital presence

Hypha Discovery financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hypha Discovery leadership team

Management profile

Number of profiles

Profiles4 records

Hypha Discovery funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hypha Discovery M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hypha Discovery

What does Hypha Discovery do?

Hypha Discovery is a UK-based Contract Research Organization (CRO) that delivers custom metabolite synthesis, purification, and identification (MetID) services for pharmaceutical and agrochemical R&D clients. The company combines chemical synthesis, recombinant enzymes (including its proprietary PolyCYPs and PolyUGTs screening kits), and microbial/mammalian biotransformation to produce drug and pesticide metabolites, including difficult-to-synthesise CYP and non-CYP phase I metabolites, glucuronides, and conjugates, with structure elucidation by LC-MS/MS and quantitative NMR.

Is Hypha Discovery a public or private company?

Hypha Discovery is a private company. It is classified as unknown and is currently operating.

When was Hypha Discovery founded?

Hypha Discovery was founded in 2004. It employs 11 to 50 people.

Where is Hypha Discovery based?

Hypha Discovery is headquartered in Abingdon, United Kingdom, in the Europe region.

How does Hypha Discovery make money?

Six revenue lines are on record. MetID Services are the primary driver. The others are metabolite Synthesis, purification Services, screening Kits (PolyCYPs, PolyUGTs), custom Natural Product Synthesis and contract Fermentation.

Who are Hypha Discovery's main competitors?

Direct peers on record are Sekisui Xenotech, BioIVT (BioreclamationIVT), Absorption Systems (Eurofins Discovery) and Inotiv. Broad incumbents are Eurofins Discovery, Charles River Laboratories, Pharmaron, WuXi AppTec and Thermo Fisher Scientific (Patheon / PPD). Sai Life Sciences is listed as a regional player.

Does Hypha Discovery have an API?

No public API is recorded for Hypha Discovery.

What industry is Hypha Discovery in?

Hypha Discovery's product category is Drug Metabolism Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAFAC, DMPK / ADME & Bioanalysis. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales